ArticleBlood2013
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia.Cancer medicine · 2024Review
- Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.Nature cancer · 2024Article
- Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.Nutrients · 2023Article
- Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma.Pharmaceutics · 2023Article
- Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of theHaematologica · 2021Article
- Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans.Science translational medicine · 2020Article
- A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.Nature communications · 2019Article
- Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma.Advances in cell and gene therapy · 2018Article
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.Nature medicine · 2018Article
- Consecutive epigenetically-active agent combinations act inOncotarget · 2018Article
- Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia.Haematologica · 2017Article
- miRNAs in acute myeloid leukemia.Oncotarget · 2017Review
- The role of the proteasome in AML.Blood cancer journal · 2016Review
- MicroRNA-29b mediates altered innate immune development in acute leukemia.The Journal of clinical investigation · 2016Article
- Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.Haematologica · 2016Article
- Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.The Journal of experimental medicine · 2015Article
- Article
- The role of miR-29b in cancer: regulation, function, and signaling.OncoTargets and therapy · 2015Review
- Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.Experimental hematology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Funding
Abstract
The coexpression of the MLL partial tandem duplication (PTD) and the FLT3 internal tandem duplication (ITD) mutations associate with a poor outcome in cytogenetically normal acute myeloid leukemia (AML). In mice, a double knock-in (dKI) of Mll(PTD/wt) and Flt3(ITD/wt) mutations induces spontaneous AML with an increase in DNA methyltransferases (Dnmt1, 3a, and 3b) and global DNA methylation index, thereby recapitulating its human AML counterpart. We determined that a regulator of Dnmts, miR-29b, is downregulated in bone marrow of dKI AML mice. Bortezomib exerted a dose-dependent increase in miR-29b expression in AML blasts ex vivo, followed by decreased Dnmts, reduced proliferation, and increased apoptosis. In vivo, bortezomib was not active against dKI AML, yet liposomal-encapsulated bortezomib, as a single agent, reversed downregulation of miR-29b in vivo and induced a long-term (90-day) disease-free remission in 80% of dKI AML mice that exhibited high leukemic burden at the start of therapy, yet showed no signs of relapse at autopsy. Taken together, these data support that liposomal bortezomib, as a single agent, eradicates Mll(PTD/wt):Flt3(ITD/wt) AML in mouse and may represent a powerful and potentially curative approach to high-risk human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.